168079-17-2

Upstream product

• 3958-60-9 2-nitrophenylmethyl bromide 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 
• 22162-51-2 1-(2-Nitrobenzyl)-2-pyrrolecarboxaldehyde 
• 1003-29-8 2-pyrrole aldehyde 
• 22162-53-4 10,11-dihydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine 
• 67579-92-4 3-methoxy-4-nitrobenzoic acid chloride 
• 168079-16-1 10,11-Dihydro-10-(3-methoxy-4-nitrobenzoyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine 

Relevant academic research and scientific papers

Novel tricyclic diazepines tocolytic oxytocin receptor antagonists

This invention provides novel tricyclic diazepine compounds as well as methods and pharmaceutical compositions utilizing these compounds for the treatment and/or prevention and/or suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including treatment of preterm labor, dysmenorrhea, endometritis, and for suppressing labor prior to caesarean delivery. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.

Tricyclic diazepine vasopressin antagonists and oxytocin antagonists

Tricyclic diazepines of the formula: STR1 wherein A, B, D, E, F, Y and Z are defined in the specification which compounds have vasopressin and oxytocin antagonist activity.